Troxevasin 300 mg, 50 capsules
- $39.00
The instruction for medical use
of TROKSEVAZIN® medicine
the Trade name
of Troksevazin®
the International unlicensed
name Trokserutin Lekarstvennaya a form
of the Capsule of 300 mg
Structure
One capsule contains
active agent - trokserutin 300 mg
excipients: magnesium stearate, lactoses monohydrate
structure of a solid gelatin capsule: dioxide (E171), gelatin sanst yellow (E110), quinoline (E104), the titan.
The description
Solid cylindrical gelatin capsules No. 1, with the body and a lid of yellow color.
Contents of capsules - powder from yellow till yellowy-brown color, are allowed existence of conglomerates which when pressing break up.
Pharmacotherapeutic group
the Drugs reducing permeability of capillaries. Bioflavonoids.
C05CA04 code
the Pharmacological
Pharmacokinetics Absorption Later properties of intake is quickly adsorbed by automatic telephone exchange from the digestive tract (DT), easily there passes the gistogematichesky barrier. The maximum concentration of a trokserutin in plasma is noted in 2 hours, therapeutic concentration in blood plasma is maintained within 8 hours.
Metabolism
Is metabolized in a liver with formation of 2 metabolites.
Removal
Elimination half-life - about 24 hours. Trokserutin is brought mainly with bile, only an insignificant part with urine. The barrier does not get through krovemozgovy. Penetration through a placental barrier is not considerable, in the minimum quantities is removed with breast milk.
A pharmacodynamics
the Drug used at disturbances of venous blood circulation, a bioflavonoid. Reduces permeability and fragility of capillaries, renders antioxidant, antiedematous, venotoniziruyushchy, angioprotektorny and anti-inflammatory action. Reduces puffiness, pain, trophic disturbances and other pathological changes caused by chronic venous insufficiency. Troxevasinum affects capillaries, increasing their stability and reducing permeability of a vascular wall of veins, blocks venodilatiruyushchy effect of a histamine, bradykinin, acetylcholine. Has anti-inflammatory effect on paravenous fabric, has kapillyarotonichesky activity and antiagregantny effect. Favorable impact on walls of vessels which function constantly changes at development of varicose veins Troxevasinum improves a course of chronic venous insufficiency and promotes prevention of development of its complications. Drug participates in oxidation-reduction processes, inhibition of hyaluronidase and development of antioxidant activity. Working as antioxidant, prevents oxidation of ascorbic acid and adrenaline, suppresses peroxide oxidation of lipids. Inhibits aggregation of thrombocytes. Promotes reduction of trophic disturbances at a varicose syndrome.
Indications
as a part of complex therapy:
- prevaricose and varicose syndromes
- superficial thrombophlebitis, phlebitis, a periphlebitis and a postflebitichesky
syndrome
- chronic venous insufficiency
- trophic disturbances in a varicosity
- hemorrhoids
- a retinopathy
- in the combined treatment of contusions, stretchings, dislocations, muscular pains
- hypostases and pains after injuries and in a varicosity, varicose
dermatitis
the Route of administration and doses
of Troksevazin of the capsule are accepted inside at meal time.
A usual dose - on 2 capsules a day. Treatment continues before total disappearance of symptoms and hypostasis, usually 2 weeks. The supporting treatment – on 1 capsule a day within 3-4 weeks. This treatment can be combined with use of Troksevazin® of gel.
Success of treatment of Troksevazinom depends on regularity of its reception, the correct dosage and duration of therapy. Clinical experience shows that sometimes the desirable effect is observed at the doses exceeding 600 mg a day. The maximum daily dose makes 900 mg (on 1 capsule 3 times a day).
It is impossible to accept doses stated above to compensate the missed reception.
Side effects
the General frequency of the undesirable phenomena is comparable to that for placebo.
Frequency of emergence of side reactions is estimated thus: 'it is very frequent' - & gt, 1/10, is 'frequent' – from & gt, 1/100 to & lt, 1/10, 'sometimes' – from & gt, 1/1000 to & lt, 1/100, is 'rare' – from & gt, 1/10000 to & lt, 1/1000, 'it is very rare' - & lt, 1/10000.
Sometimes
- nausea, vomiting, diarrhea, dyspepsia
- urticaria and
naggers Redko
- a headache and a sleep disorder
-
Contraindication GIT erosive cankers
- hypersensitivity to a trokserutin or any of
excipients
- pregnancy (1 trimester), the lactation period
- children's age up to 18 years
- the lactose intolerance, a galactosemia or glucosic galaktozny
a sprue
Medicinal interactions
Strengthens effect of ascorbic acid on structure and permeability of a vascular wall.
Special instructions
use Drug with care at patients with a serious illness of a liver and gall bladder.
Troksevazin accept at meal time as it irritates a mucous membrane of a stomach.
In view of presence of dyes (E110), drug treatment can cause allergic reactions including asthma. The risk of an allergy is higher at patients with hypersensitivity to aspirin.
Pregnancy
it is necessary to Apply Troksevazin during pregnancy (II and III trimesters) if the expected advantage for mother prevails over possible risk for a fruit.
The feature of influence on ability to run the vehicle or potentially dangerous
Troksevazin mechanisms does not influence ability of control of the vehicle and works with moving mechanisms.
Overdose
Symptoms – strengthening of side effects.
Treatment is symptomatic, if necessary it is possible to appoint peritoneal dialysis.
A form of release and packing
On 10 capsules in blister strip packaging from a film of PVC and printing aluminum foil or PVH/PVDH and printing aluminum foil.
On 5 blister strip packagings together with the instruction for use in the state and Russian languages put in a cardboard pack.
To Store storage conditions at a temperature not above 25 °C.
To store out of children's reach!
A period of storage
of 5 years
Drug cannot be used after the expiration date specified on packing.
Prescription status
Without prescription
ABP Balkanpharma-Razgrad Producer,
Boole. April revolt,
No. 68 7200 Razgrad, Bulgaria
Ph. (+359 84)
660 999 Fax (+359 84) 634,272
E-mail: mainraz@actavis.bg
the Owner of the registration certificate
Balkanpharma-Razgrad the ABP, Bulgaria
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims on quality of products from consumers
Representation Aktavis International Ltd. in
Almaty Republic of Kazakhstan, 050009, Almaty, Mukanov St., 241, office 1.
Ph./fax: 8 (727) 313 74 30, 313 74 31, 313 74 32,
E-mail address: actavis@actavis.kz, website: www.actavis.com
of TROKSEVAZIN® medicine
the Trade name
of Troksevazin®
the International unlicensed
name Trokserutin Lekarstvennaya a form
of the Capsule of 300 mg
Structure
One capsule contains
active agent - trokserutin 300 mg
excipients: magnesium stearate, lactoses monohydrate
structure of a solid gelatin capsule: dioxide (E171), gelatin sanst yellow (E110), quinoline (E104), the titan.
The description
Solid cylindrical gelatin capsules No. 1, with the body and a lid of yellow color.
Contents of capsules - powder from yellow till yellowy-brown color, are allowed existence of conglomerates which when pressing break up.
Pharmacotherapeutic group
the Drugs reducing permeability of capillaries. Bioflavonoids.
C05CA04 code
the Pharmacological
Pharmacokinetics Absorption Later properties of intake is quickly adsorbed by automatic telephone exchange from the digestive tract (DT), easily there passes the gistogematichesky barrier. The maximum concentration of a trokserutin in plasma is noted in 2 hours, therapeutic concentration in blood plasma is maintained within 8 hours.
Metabolism
Is metabolized in a liver with formation of 2 metabolites.
Removal
Elimination half-life - about 24 hours. Trokserutin is brought mainly with bile, only an insignificant part with urine. The barrier does not get through krovemozgovy. Penetration through a placental barrier is not considerable, in the minimum quantities is removed with breast milk.
A pharmacodynamics
the Drug used at disturbances of venous blood circulation, a bioflavonoid. Reduces permeability and fragility of capillaries, renders antioxidant, antiedematous, venotoniziruyushchy, angioprotektorny and anti-inflammatory action. Reduces puffiness, pain, trophic disturbances and other pathological changes caused by chronic venous insufficiency. Troxevasinum affects capillaries, increasing their stability and reducing permeability of a vascular wall of veins, blocks venodilatiruyushchy effect of a histamine, bradykinin, acetylcholine. Has anti-inflammatory effect on paravenous fabric, has kapillyarotonichesky activity and antiagregantny effect. Favorable impact on walls of vessels which function constantly changes at development of varicose veins Troxevasinum improves a course of chronic venous insufficiency and promotes prevention of development of its complications. Drug participates in oxidation-reduction processes, inhibition of hyaluronidase and development of antioxidant activity. Working as antioxidant, prevents oxidation of ascorbic acid and adrenaline, suppresses peroxide oxidation of lipids. Inhibits aggregation of thrombocytes. Promotes reduction of trophic disturbances at a varicose syndrome.
Indications
as a part of complex therapy:
- prevaricose and varicose syndromes
- superficial thrombophlebitis, phlebitis, a periphlebitis and a postflebitichesky
syndrome
- chronic venous insufficiency
- trophic disturbances in a varicosity
- hemorrhoids
- a retinopathy
- in the combined treatment of contusions, stretchings, dislocations, muscular pains
- hypostases and pains after injuries and in a varicosity, varicose
dermatitis
the Route of administration and doses
of Troksevazin of the capsule are accepted inside at meal time.
A usual dose - on 2 capsules a day. Treatment continues before total disappearance of symptoms and hypostasis, usually 2 weeks. The supporting treatment – on 1 capsule a day within 3-4 weeks. This treatment can be combined with use of Troksevazin® of gel.
Success of treatment of Troksevazinom depends on regularity of its reception, the correct dosage and duration of therapy. Clinical experience shows that sometimes the desirable effect is observed at the doses exceeding 600 mg a day. The maximum daily dose makes 900 mg (on 1 capsule 3 times a day).
It is impossible to accept doses stated above to compensate the missed reception.
Side effects
the General frequency of the undesirable phenomena is comparable to that for placebo.
Frequency of emergence of side reactions is estimated thus: 'it is very frequent' - & gt, 1/10, is 'frequent' – from & gt, 1/100 to & lt, 1/10, 'sometimes' – from & gt, 1/1000 to & lt, 1/100, is 'rare' – from & gt, 1/10000 to & lt, 1/1000, 'it is very rare' - & lt, 1/10000.
Sometimes
- nausea, vomiting, diarrhea, dyspepsia
- urticaria and
naggers Redko
- a headache and a sleep disorder
-
Contraindication GIT erosive cankers
- hypersensitivity to a trokserutin or any of
excipients
- pregnancy (1 trimester), the lactation period
- children's age up to 18 years
- the lactose intolerance, a galactosemia or glucosic galaktozny
a sprue
Medicinal interactions
Strengthens effect of ascorbic acid on structure and permeability of a vascular wall.
Special instructions
use Drug with care at patients with a serious illness of a liver and gall bladder.
Troksevazin accept at meal time as it irritates a mucous membrane of a stomach.
In view of presence of dyes (E110), drug treatment can cause allergic reactions including asthma. The risk of an allergy is higher at patients with hypersensitivity to aspirin.
Pregnancy
it is necessary to Apply Troksevazin during pregnancy (II and III trimesters) if the expected advantage for mother prevails over possible risk for a fruit.
The feature of influence on ability to run the vehicle or potentially dangerous
Troksevazin mechanisms does not influence ability of control of the vehicle and works with moving mechanisms.
Overdose
Symptoms – strengthening of side effects.
Treatment is symptomatic, if necessary it is possible to appoint peritoneal dialysis.
A form of release and packing
On 10 capsules in blister strip packaging from a film of PVC and printing aluminum foil or PVH/PVDH and printing aluminum foil.
On 5 blister strip packagings together with the instruction for use in the state and Russian languages put in a cardboard pack.
To Store storage conditions at a temperature not above 25 °C.
To store out of children's reach!
A period of storage
of 5 years
Drug cannot be used after the expiration date specified on packing.
Prescription status
Without prescription
ABP Balkanpharma-Razgrad Producer,
Boole. April revolt,
No. 68 7200 Razgrad, Bulgaria
Ph. (+359 84)
660 999 Fax (+359 84) 634,272
E-mail: mainraz@actavis.bg
the Owner of the registration certificate
Balkanpharma-Razgrad the ABP, Bulgaria
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims on quality of products from consumers
Representation Aktavis International Ltd. in
Almaty Republic of Kazakhstan, 050009, Almaty, Mukanov St., 241, office 1.
Ph./fax: 8 (727) 313 74 30, 313 74 31, 313 74 32,
E-mail address: actavis@actavis.kz, website: www.actavis.com
Related Products
Et al. Kade Pharmaceutical Factory GmbH (Germany)
Posterizan® rectal ointment 25 g
$16.50
Out Of Stock